Bitcoin halving
What does that mean?
$2.79T
Total marketcap
$119.67B
Total volume
BTC 49.87%     ETH 15.33%
Dominance

Cytokinetics, Incorporated CYTK Stock

70.11 USD {{ price }} -1.820478% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
7.22B USD
LOW - HIGH [24H]
69.96 - 71.86 USD
VOLUME [24H]
1.61M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-5.45 USD

Cytokinetics, Incorporated Price Chart

Cytokinetics, Incorporated CYTK Financial and Trading Overview

Cytokinetics, Incorporated stock price 70.11 USD
Previous Close 35.01 USD
Open 34.87 USD
Bid 0 USD x 1000
Ask 0 USD x 800
Day's Range 34.57 - 35.95 USD
52 Week Range 32.96 - 55.8 USD
Volume 884.61K USD
Avg. Volume 888.96K USD
Market Cap 3.39B USD
Beta (5Y Monthly) 0.797183
PE Ratio (TTM) N/A
EPS (TTM) -5.45 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 60.93 USD

CYTK Valuation Measures

Enterprise Value 3.44B USD
Trailing P/E N/A
Forward P/E -8.018099
PEG Ratio (5 yr expected) -0.55
Price/Sales (ttm) 34.568066
Price/Book (mrq) N/A
Enterprise Value/Revenue 35.037
Enterprise Value/EBITDA -9.425

Trading Information

Cytokinetics, Incorporated Stock Price History

Beta (5Y Monthly) 0.797183
52-Week Change -12.66%
S&P500 52-Week Change 20.43%
52 Week High 55.8 USD
52 Week Low 32.96 USD
50-Day Moving Average 37.51 USD
200-Day Moving Average 41.9 USD

CYTK Share Statistics

Avg. Volume (3 month) 888.96K USD
Avg. Daily Volume (10-Days) 764.23K USD
Shares Outstanding 95.64M
Float 94.85M
Short Ratio 11.59
% Held by Insiders 0.85%
% Held by Institutions 115.10%
Shares Short 9.46M
Short % of Float 16.98%
Short % of Shares Outstanding 9.89%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1:6

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) -378.18%
Gross Margin -179.74%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -26.54%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 98.05M USD
Revenue Per Share (ttm) 1.06 USD
Quarterly Revenue Growth (yoy) 301.79%
Gross Profit (ttm) -146225000 USD
EBITDA -364496992 USD
Net Income Avi to Common (ttm) -430799008 USD
Diluted EPS (ttm) -4.49
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 663.96M USD
Total Cash Per Share (mrq) 6.94 USD
Total Debt (mrq) 751.06M USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 9.049
Book Value Per Share (mrq) -2.395

Cash Flow Statement

Operating Cash Flow (ttm) -394991008 USD
Levered Free Cash Flow (ttm) -209217632 USD

Profile of Cytokinetics, Incorporated

Country United States
State CA
City South San Francisco
Address 350 Oyster Point Boulevard
ZIP 94080
Phone 650 624 3000
Website https://www.cytokinetics.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 409

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Q&A For Cytokinetics, Incorporated Stock

What is a current CYTK stock price?

Cytokinetics, Incorporated CYTK stock price today per share is 70.11 USD.

How to purchase Cytokinetics, Incorporated stock?

You can buy CYTK shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Cytokinetics, Incorporated?

The stock symbol or ticker of Cytokinetics, Incorporated is CYTK.

Which industry does the Cytokinetics, Incorporated company belong to?

The Cytokinetics, Incorporated industry is Biotechnology.

How many shares does Cytokinetics, Incorporated have in circulation?

The max supply of Cytokinetics, Incorporated shares is 103.01M.

What is Cytokinetics, Incorporated Price to Earnings Ratio (PE Ratio)?

Cytokinetics, Incorporated PE Ratio is now.

What was Cytokinetics, Incorporated earnings per share over the trailing 12 months (TTM)?

Cytokinetics, Incorporated EPS is -5.45 USD over the trailing 12 months.

Which sector does the Cytokinetics, Incorporated company belong to?

The Cytokinetics, Incorporated sector is Healthcare.

Cytokinetics, Incorporated CYTK included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16379.46 USD
-0.12
4.77B USD 16347.38 USD 16420.92 USD 4.77B USD
NASDAQ Composite Total Return I XCMP 19904.22 USD
-0.12
19865.24 USD 19954.6 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2657.07 USD
+0.1
2653.57 USD 2668.1 USD
NASDAQ Biotechnology NBI 4429.97 USD
-0.36
4426.59 USD 4461.88 USD
NASDAQ HealthCare IXHC 1011.84 USD
-0.04
1011.35 USD 1017.55 USD
NASDAQ Global Select Market Com NQGS 7966.15 USD
-0.13
7950.14 USD 7986.36 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD